You are here

Article Text

Article menu
Download PDFPDF
DTB select
Safety update: psychiatric and sexual adverse effects with finasteride

https://doi.org/10.1136/dtb.2024.000036

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Key learning points

    • Finasteride is licensed for the treatment of benign prostatic hyperplasia and male pattern hair loss.

    • A previous safety alert has highlighted the risk of depression and suicidal thoughts associated with finasteride.

    • There is a need to raise awareness among healthcare professionals and patients of the risk of psychiatric and sexual adverse effects.

    The Medicines and Healthcare products Regulatory Agency (MHRA) has reminded healthcare professionals to warn patients that finasteride is associated with psychiatric and sexual adverse effects that may persist after treatment has stopped.1

    Overview

    The MHRA has conducted a review into the safety of finasteride following concerns raised by patients about the apparent lack of awareness among healthcare professionals and patients of the risk of depression and suicidal thoughts associated with …

    View Full Text

    Footnotes

    • Contributors DTB Team.

    • Provenance and peer review Commissioned; internally peer reviewed.